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Despite remarkable therapeutic advances have been made in the last few decades, non-small cell lung cancer (NSCLC) is still one of
the leading causes of death worldwide. Brain metastases are a common complication of a wide range of human malignancies and in
particular NSCLC. Brain-derived neurotrophic factor (BDNF), binding its high-affinity tyrosine kinase B receptor, has been shown
to promote cancer progression and metastasis. We hereby investigated the expression of the BDNF and its TrkB receptor in its full-
length and truncated isoform T1, in samples from primary adenocarcinomas (ADKs) of the lung and in their metastasis to evaluate
if their expression was related to preferential tumor entry into the central nervous system (CNS). By immunohistochemistry, 80% of
the ADKs that metastasize to central nervous system expressed TrkB receptor compared to 33% expressing of ADKs without CNS
metastasis. Moreover, ADKs with CNS metastasis showed an elevated expression of the full-length TrkB receptor. The TrkB
receptor FL/T1 ratio was statistically higher in primary ADKs with brain metastasis compared to ADKs without brain
metastasis. Our data indicate that TrkB full-length isoform expression in primary ADK cells may be associated with higher risk
to develop brain metastasis. Therefore, TrkB receptor may possess prognostic and therapeutic implications in lung ADK.
1. Introduction
NSCLC is an aggressive malignancy with rapid progression
and low survival rate [1]. Although the advent of targeted
therapies has significantly extended life expectancy, yet only
a small percentage of patients are currently eligible. The
majority of the advances have been made for the treatment
of lung adenocarcinomas (ADKs) which represent the
majority of the NSCLC, and that is characterized by consid-
erable molecular heterogeneity [2]. In this regard, different
molecular aberrations including EGFR, ALK, and ROS1
mutation have proved to be effective therapeutic targets [3].
Unfortunately, only less than 20% of ADK patients express
these sensible mutations, leaving the large majority of
NSCLC out of range for a targeted therapy. In addition to
that, patients inevitably acquire resistance to this form of
treatment over the time [4]. These observations highlight
the importance of improving the knowledge of NSCLC
molecular biology with the aim of developing novel molecu-
lar targets able to extend patient survival.
Neurotrophins (NTs) are a family of growth factors with
important pleiotropic function in the central and peripheral
nervous system [5]. NT family consists of principally four
peptides, the prototype nerve growth factor (NGF), brain-
derived neurotrophic factor (BDNF), the NT 3, and the NT
4/5 [6]. All these growth factors bind to the low-affinity pan
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NT P75 receptor [7]. Moreover, NTs bind specific high-
affinity tropomyosin-related kinase (Trk) receptors. BDNF
preferentially binds the TrkB, a tyrosine kinase receptor
located at the cellular membrane whose intracellular signal-
ing is implicated in neuronal survival and differentiation.
The BDNF/TRKB axis has been shown to be activated in
several human malignancies [8, 9] with important effect on
cancer cells behavior [10]. In particular, TrkB expression on
cancer cells has been associated with aggressiveness and ten-
dency to metastasize [11]. TrkB activate may be expressed in
a number of different isoforms [12]. Biological activity
required the TrkB full-length isoform (TrkB-FL). The func-
tions of the truncated isoforms (TrkB-T1 and TrkB-T2) are
unclear although under some conditions can function as
dominant negatives [13]. In addition, the release of BDNF
from cancer cells may also be involved in that cross talk
between stroma and cancer, facilitating a microenvironment
favorable for cancer metastasis. It is well known that micro-
environment may be essential for cancer cell survival and
development. Based on the well-known neurotrophic func-
tion displayed by the BDNF/TRKB axis within the nervous
system, we hypothesize that the expression of the TRKB
receptors and/or the release of neurotrophic growth factors
may allow ADK cells to survive and proliferate in a so specific
microenvironment [9]. Furthermore, we have also investi-
gated the possible role of TrkB isoforms to contribute to this
phenomenon. Therefore, the aim of the present study has
been to demonstrate if TrkB isoforms and BDNF expression
in primary ADKs of the lung may be associated with increas-
ing risk to develop metastasis to the brain.
2. Materials and Methods
2.1. Patients. We collected a total of 55 tissue samples
obtained from patients who underwent surgical lung resec-
tion or lung biopsies at Sant’Andrea Hospital between 2007
and 2019. All patients had a diagnosis of primary ADK on
the histological tissue examination. They were followed
clinically and radiologically, for almost two years from the
moment of diagnosis. None of them had received treatment
or had previous cancer history before lung surgery.
Group 1 was represented by 20 tissue lung samples of
patients with brain metastasis. Among them, only 10 patients
staged as stages II and IIIa, who underwent lung cancer resec-
tion, developed brain solitary metastasis during the follow-up
that was treated surgically. Therefore, for these patients, we
had the opportunity to process both primitive tumor and the
corresponding cerebral metastasis samples. In the same Group
1, we enrolled 10 no resectable ADKs (stages III and IV) with
brainmetastasis of which we studied the lung cancer specimens.
Group 2 was represented by 15 patients affected with ADK
of the lung stages IIIb and IV who did not develop brain metas-
tasis during their follow-up. Samples from these patients were
derived from surgical biopsies. These patients were treated with
chemotherapy or, in selected cases, by TK inhibitors.
Group 3 was represented by 20 patients affected by ADK
of the lung (stages IIIb and IV) with single or polymetastatic
disease in site different from the brain. In this group, both
lung cancer and metastatic specimens were obtained.
All the samples of each group were processed for TrkB
and BDNF immunohistochemical determination.
All patient’s characteristics are summarized in Table 1.
The study was approved by the Ethics Committee
(protocol number 1032/17).
2.2. Cancer Cell Cultures. Established human NSCLC cell line
NCI-H460 was used to better clarify the results obtained in
human cancer tissues. Cell line was obtained from the Amer-
ican Type Culture Collection (ATCC, Manassas, VA, USA)
and was cultured according to the manufacturer’s instruc-
tions. The cancer cell line H460 was used and grown under
aseptic conditions as previously detailed [14]. Briefly, the
cells were suspended in RPMI 1640 supplemented with
0.1% bovine serum albumin, 0.5mg/ml fungizone, 5mg/ml
gentamycin, 5mM ethanolamine, 10mM HEPES, 5mg/ml
transferrin, 10mMT3, 50mM selenium, 5mg/ml insulin,
and 1mg/ml hydrocortisone. The cells were cultured at
37°C in culture flasks. All cell culture reagents were obtained
from Sigma Chemical Co. (St. Louis, MO).
Cells were grown in adherence (ACC) and in spheroid
conditions. To generate spheres, cancer cells were suspended
in a Dulbecco’s modified Eagle’s medium/F12 (Invitrogen
Ltd.) supplemented with 50 ng/ml of epidermal growth factor
and 25ng/ml of bovin fetal growth factor. Spheres were
observed using a microscope Zeiss Axiovert 25, Jena, Ger-
many. After checking for single cells, the cells were pelleted
and suspended in sphere culture medium before replating
in nonadherent flasks. In these conditions, cancer cells devel-
oped high expression of cancer stem cell-associated markers
(CSC) (data not shown).
2.3. RNA Extraction, Reverse Transcription, and PCR. The
expression of full-length TRKB, TRKB-T1, in lung tissues
was studied by evaluating RNA levels. RNA from surgical
and biopsy-derived samples was collected from five 5μm
thick sections of tissue mounted on a microscopic slide.
The slides were stained in hematoxylin and eosin and evalu-
ated by the pathologist to select areas richer in tumor cells.
Total RNA was obtained using the High Pure FFPE RNA
Micro KIT (Roche Diagnostics, Germany), an isolation kit
designed to extract all nucleic acids (RNA, miRNA, and
DNA) from formalin-fixed and paraffin-embedded tissues.
TRIzol, phenol, and chloroform were used for RNA extrac-
tion from cell lines. RNA integrity was evaluated by agarose
gel electrophoresis and spectrophotometry. Four micrograms
of total RNA extracted from tissue was reverse transcribed in
a final volume of 20μL using the Fast Gene Scriptase II kit
(LS63, NIPPON Genetics Europe, RESNOVA, Italy). The
cDNA was at -20°C until further analysis. A positive control
also used cDNA obtained from RNA extracted from a sample
of diffused cerebral neoplasia. The genes of interest were
evaluated by PCR analysis using the following specific
primers: TRKB FL forward 5- TAC ATC TGT ACT AAA
ATACA-3, reverse 5- GTG TCC CCG ATG TCA TTC GC
-3, TRKB T1 forward 5- TAA AAC CGG TCG GGA ACA
TC -3 reverse 5- ACC CAT CCA GTG GGA TCT TA -3,
and BDNF forward 5- AAC AAT AAG GAC GAC GAC
TT -3 reverse 5- TGC AGT CTT TTT GTC TGC CG -3. In
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order to normalize the amount of total cDNA present in each
reaction, the B-actin gene was amplified.
2.4. Quantitative Real-Time PCR (qRT PCR). The expression
of full-length TRKB, TRKB T1, in the lung tissues of metasta-
tic and not metastatic patients was studied by evaluating
RNA levels using a SYBR Green real-time PCR assay using
the following specific primers: TRKB FL forward 5- GGCC
CAGATGCTGTCATTAT-3 reverse 5-TCCTGCTCAGG
ACAGAGGTT-3; TRKB-T1 forward 5-ATCCCTTCCAC
AGACGTCAC-3 reverse 5- CCATCCAGTGGGATCTTAT
GAAAC-3; and BDNF forward 5- AACAATAAGGACGC
AGACTT-3 reverse 5-TGCAGTCTTTTTGTCTGCCG-3.
To normalize the total amount of cDNA present in each reac-
tion, the β-actin gene was amplified: actin forward 5- CGGT
TCCGCTGCCCTGAG-3 reverse 5- TGGAGTTGAAGGTA
GTTTCGTGGAT-3. The data have been expressed as rela-
tive units (UR) to control.
Levels of full-length TRKB, TRKB-T1, and BDNF were
also measured from 2 stable cell lines derived from lung
adenocarcinoma (WT 02/19/18, SPHER-MEP 02/21/18)
which differed in the type of growth, adherent or spheroidal.
2.5. Immunohistochemistry. Histological sections fixed in
formalin and included in paraffin were immunostained with
the following antibodies: rabbit anti-human TrkB antibody
(sc-12 rabbit polyclonal affinity purified antibody raised
against a peptide mapping within the C-terminal cytoplasmic
domain of TrkB of mouse origin, Santa Cruz Biotechnology,
Dallas, Texas USA) dilution 1 : 500; rabbit anti-human
-BDNF polyclonal antibody (H20, sc-548; epitope mapping
at the N-terminus of the mature chain of mature NGF of
human origin, Santa Cruz Biotechnology, Dallas, Texas
USA) dilution 1 : 1000 dilution. After incubation, slides were
exposed to anti-rabbit secondary antibody (1 : 100). The
product of immune reaction was revealed using the three
steps labeled the streptavidin–biotin–immunoperoxidase
technique (LSAB2, DAKO, Glostrup, Denmark). The
sections were then washed, dehydrated, mounted, and
viewed under a light microscope. The analysis of the results
was independently performed by two expert pathologists.
The staining was evaluated as percentage of positive cells.
Cases with more than 5% positive cancer cells were classified
as positive. Cases with less than 5% of positive cancer cells
were considered negative. The immunohistochemical expres-
sion of the TRKB and BDNF protein was also evaluated as
color intensity (1, low intensity; 2, medium intensity; and 3,
high intensity). No specific binding was obtained by antibod-
ies preabsorbed with the corresponding blocking peptides
(10μg/ml).
2.6. Statistics. Data were expressed as mean ± standard
deviation (SD). The chi-square test or Fisher’s exact test
was used for categorical data, and Student’s t-test was used
for continuous data. Statistical analysis was performed by
using GraphPad, and a p value < 0.05 was considered signif-
icant. All in vitro experiments were performed in triplicate.
3. Results
3.1. Immunohistochemical Expression of TrkB and BDNF.
The expression of TrkB was demonstrated by immunohisto-
chemistry (IHC). The expression of TrkB was detected in
paraffin-embedded section obtained from samples of lung
cancer and brain, skin, bone, and liver metastases. The reac-
tion product was visualized in brown in tumor immunoposi-
tive cells, within the cytoplasm. The results showed a
statistically significant difference, in the TrkB receptor
immunohistochemical expression, in tissue samples obtained
from ADKs of the lung obtained from patients belonging to
Group 1 (lung cancer with brain metastasis) and Group 2
(lung cancer without brain metastasis) (1:9 ± 1:1 and 0:7 ±
0:9, respectively) expressed in arbitrary unit (p = 0:017)
(Figure 1). On the contrary, the expression of BDNF is higher
in the Group 2 (1:33 ± 0:5 in Group 1; 1:88 ± 1:3 in Group 2)
(p = 0:26) (Figure 1). The number of patients that expressed
TrkB in medium-high intensity in Group 1 versus Group 2
was, respectively, 16/20 (80%) and 5/15 (33%) (Figure 2).
TrkB and BDNF were also demonstrated by IHC in
patients belonging to Group 1 in both lung cancer and the
corresponding brain metastasis. The expression of TrkB
was higher in brain metastasis than corresponding primitive
lung cancer (2:8 ± 0:4 vs. 1:9 ± 1:1) (p = 0:02) (Figure 3).
Similarly, BDNF was more expressed in metastasis than in
the corresponding primitive lung cancer from which they
originated (2:2 ± 0:6 vs. 1:3 ± 0:5) (p = 0:004) (Figure 3).
Finally, the expression of TrkB and BDNF was estimated
on sample tissue obtained from metastasis of lung cancer
different from brain, in particular, liver (n = 13), bone
(n = 2), and skin (n = 5) (Figure 4). In these samples, BDNF
Table 1: Demographic and clinical characteristics of patients studied.
Patients Group 1 (n = 20) Group 2 (n = 15) Group 3 (n = 20)
Age 62:90 + 7:6 73 + 4:2 61 + 15:75








Lung cancer (ADKs) 20 15 20
Brain metastasis 10 nd nd
Bone (2), skin (5), and liver (13) metastases nd nd 20
nd: not detected.
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antibody generated a specific immunostaining in cancer cells
in the 75% of the samples. On the contrary, we detected a
specific TrkB immunostaining in only one sample of liver
metastasis.
3.2. Real-Time Quantitative Reverse Transcription PCR. Since
our immunohistochemical analysis was unable to discrimi-
nate which receptor isoform (full-length TRKB or TRKB-
T1) prompted us to identify the relative expression of the dif-
ferent isoforms by further and more sensitive investigation
techniques. qRT-PCR allows us to enable reliable detection
and measurement of products generated during each cycle
of PCR process. Thus, we demonstrated the expression of
the full-length (FL) TrkB receptor and truncated (T1)
isoforms. The expression of the FL is higher in Group 1 com-
pared to Group 2 (1:025 ± 0:68 and 0:5 ± 0:96, respectively).
Contrarily, the T1 isoform was more expressed in Group 2
(Figure 5). Interestingly, the FL/T1 ratio confirmed this
behavior, showing that patients belonging to the Group 1
had a statistically higher ratio in comparison with Group 2
(6:59 ± 7:10 vs. 0:48 ± 0:94) (p = 0:014) (Figure 5).
3.3. TrkB Receptor and BDNF in Primary Adherent and
Spheroid Cell Cultures. Spheroid cancer cell mimics the char-
acteristics of cancer stem cells with migratory capacity and
resistance to chemotherapy resembling the “in vitro” coun-
terpart of metastatic cells [15].
For this reason, we compared the TrkB and BDNF levels
in spheroid versus adherent cancer cells. Data obtained by
RT-PCR and qRT-PCR showed that the expression of both
isoforms was higher in cell grown in adherence. Moreover,
the FL/T1 ratio was higher in cell grown under spheroid con-
ditions (1:07 ± 0:05 and 1:14 ± 0:02 in three independent
experiments) (p < 0:05) (Figure 6).
4. Discussion
Lung cancer is the leading cause of cancer-related death
worldwide. Brain metastasis occurs in almost 40% of NSCLC
patients [16] and is associated with a poor prognosis [17].
However, the factors that can favor brain metastasis in
NSCLC are still poorly understood. Here, we show that
patients affected with ADK express higher levels of TrkB in
the presence of brain metastatic disease.
In the last few decades, it has become increasingly clear
that NTs and their TrkB receptors have a wide range of bio-





































Figure 1: Immunohistochemical detection of TrkB and BDNF protein expression in sections of primitive ADKs of the lung with (Group 1) or
without (Group 2) brain metastasis. The histograms summarize the results obtained. A statistically significant increase of TrkB protein
expression was observed in samples from primitive ADK in Group 1 compared with Group 2. The BDNF protein expression was higher
in Group 2 in comparison with Group 1. Notice the anatomical localization of BDNF and TrkB protein expression in ADK cell. BDNF
antibodies generated a prevalent nuclear dark brown immunoreaction. The TrkB antibody generated a cytoplasmic and cell membrane
immunoreaction. A clear and specific TrkB and BDNF immunostaining was documented in ADKs cells in both primitive and brain
metastasis in Group 1. Contrarily, in Group 2, a strong and specific BDNF immunostaining was documented in brain metastasis, but not

















Figure 2: Distribution among the groups of TrkB intensity
immunostaining (0: expression < 5%; 1: low intensity; 2: moderate
intensity; and 3: high intensity) detected in sections of primitive
ADKs of the lung with (Group 1) and without (Group 2) brain
metastasis. The results are the mean of three independent expert
pathologist evaluation. ×20.
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lung, NT and their high-affinity receptors have been shown
to be present in tumor cells [18]. Moreover, the TrkB recep-
tor expression has been often associated with unfavorable
prognosis [19]. Furthermore, we previously demonstrated
that TrkB expression in cancer cells promotes epithelial to
mesenchymal transition and that its inhibition results in a
less-aggressive phenotype [20]. Taken together, these obser-
vations point to TrkB/NT axis as a promising target for the
treatment of lung cancer.
TrkB possesses at least 3 splice variants: the catalytic tyro-
sine kinase receptor and two different isoforms that lack the
intracellular kinase domain [21] named T1 and T2. Usually,
T1 and T2 receptors are able to attenuate or inhibit full-
length activation when coexpressed with the full length [22].
To this end, coexpression of BDNF and TrkB is often
responsive of poor prognosis and cancer progression and
migration in several tumor types [23]. Moreover, T1 expres-

























Figure 3: Immunohistochemical detection of TrkB and BDNF protein expression in section samples obtained by Group 1 (ADK with brain
metastasis). (a) The histograms summarize the results obtained. A statistical significant increase of TrkB and BDNF protein expression was
observed in samples from metastasis compared with relative primitive ADKs. (b) Notice the anatomical localization of BDNF and TrkB
protein expression in ADK cells. A strong specific immunostaining was clearly documented in both primitive ADKs and brain metastasis
(a–d). The data are the mean ± SD of different experiments performed in triplicate. ADK, primitive ADKs; BM, corresponding brain




















Figure 4: Immunohistochemical detection of BDNF protein expression in section of metastasis from the skin, liver, and bone. The BDNF
immunostaining was strongly expressed in the different metastatic sites studied (a, b). Note the specific clear immunostaining within
















Figure 5: qRT-PCR. The histogram emphasizes the elevated TrkB
FL/T1 ratio in primary ADKs of the lung with brain metastasis.
The data are the mean ± SD of different experiments performed in
triplicate. ADK, primitive ADKs; BM, corresponding brain
metastasis. ∗p < 0:01.
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outcomes. Our data firstly show that ADKs with brain metas-
tasis are more likely to express FL TrkB then the truncated
isoform. This data would confirm the inhibitor role for
TrkB-T1 receptor, while the metastatic involvement of the
CNS appears to be a more frequent complication in patients
with the exclusive or prevalent full-length TrkB expression.
The TrkB FL/T1 ratio may be a potential feature to hypothe-
size the possible risk to develop CNS metastasis.
The BBB is a complex anatomical barrier, and the mecha-
nism by which cancer cells pass through is still debated [22]. It
is in fact known that the blood brain barrier (BBB) remains
partially intact in experimental brain metastases [24]. Adhe-
sion interaction between metastatic cancer cell and activated
endothelial cells mediated by integrins and vascular cell adhe-
sion molecules (in particular VCAM-1) upon activation by
inflammatory stimuli may represent a key mechanism [22].
Our data show that BDNF levels are increased in ADK
with brain metastasis. Interestingly enough, BDNF has been
previously shown to be the ligand for the alpha9beta1
integrin whose activity could be related to its high cross-
reactivity with a variety of endogenous ligands such as
VCAM-1, tenascin C, and osteopontin [25–29]. The binding
of BDNF with this receptor displays complex proliferative
and migratory activity and may potentially promote migra-
tion through the BBB [30]. Moreover, among factors that
promote vascular proliferation and neoangiogenesis, BDNF
has been shown to increase VEGF release enhancing angio-
genesis through a signal transduction pathway that involves
the TrkB receptor and the hypoxia-inducing factor- (HIF-)
1α expression [31].
Contrarily to primary cancer cells, in brain metastasis, we
have documented an increasing expression of BDNF, which
may be responsible for favoring cancer engraftment and
metastatic progression. It is known that disseminated cancer
cells derived from primary tumor, possessing a mesenchymal
phenotype, once engrafted into the brain, may undergo a
reverse process known as mesenchymal to epithelial transi-
tion; the transition actions for EMT and MET should be
critical to metastasis or demetastasis process [32]. This phe-
nomenon may explain the different TrkB receptor and BDNF
expression observed between primary and metastatic cancer
cells derived from the same patients. BDNF may be
extremely important for the survival of metastatic cancer
cells within the central nervous system. It is important to
underline that metastases into CNS are preferentially located
in the brain areas in which higher levels of BDNF are demon-
strated. Interestingly, in our cases, brain metastases are
mainly located in the brain areas request in BDNF like frontal
and parietal cortexes [17].
Although our data are based on a small-case series, it may
stimulate further analysis for possible therapeutic application.
5. Conclusion
In ADKs of the lung, TrkB receptor expression in its FL iso-
form is often associated with metastatic brain disease. On the
contrary, the T1 truncated isoform share a protective role.
The TrkB FL/T1 ratio determinate in primary ADKs of the
lung may be considered a potential prognostic factor able to
predict the risk to develop CNS metastasis.
Data Availability
The data used to support the findings of this study are avail-
able from Lombardi Mariangela upon request.
Conflicts of Interest
The author declares that there is no conflict of interest that
could be perceived as prejudicing the impartiality of the
research reported.
Authors’ Contributions
Prof. Alberto Ricci developed the original idea and the proto-
col, wrote the manuscript, and is the guarantor. Michela
D’Ascanio contributed to abstracting and analyzing data
and writing the manuscript. Lombardi Mariangela and Stefa-
nia Scarpino contributed to the development of the protocol.
All the other authors participated equally to collecting and
analyzing the data. Mariangela Lombardi and Michela D’As-
canio contributed equally to this work.
Acknowledgments
This study was aided by the by Progetto Ateneo 2018, grant
number RM11816422218F91.
References
[1] L. A. Torre, R. L. Siegel, E. M. Ward, and A. Jemal, “Global
cancer incidence and mortality rates and trends–an update,”
Cancer Epidemiology, Biomarkers & Prevention, vol. 25,
no. 1, pp. 16–27, 2016.
[2] The Cancer Genome Atlas Research Network, “Comprehen-
sive molecular profiling of lung adenocarcinoma,” Nature,















Figure 6: RT-PCR (a) and qRT-PCR (a) to clarify the FL TrkB and
TrkB-T1 isoform expression in lung adenocarcinoma cell lines
(NCI-H460) grown in adherence (AD) or in spheroid conditions
(SP). The total amount of cDNA present in each reaction was
normalized by β-actin gene amplification. (a) The RT-PCR display
and increased expression of the FL/T1 ratio in spheroid cancer
cell. This data was confirmed by qRT-PCR (b). AD, adherent cell
lines; SP, spheroid cell lines.
6 BioMed Research International
[3] Z. Schrank, G. Chhabra, L. Lin et al., “Current molecular-
targeted therapies in NSCLC and their mechanism of resis-
tance,” Cancers, vol. 10, no. 7, 2018.
[4] P. Maione, P. C. Sacco, F. Casaluce et al., “Overcoming resis-
tance to EGFR inhibitors in NSCLC,” Reviews on Recent Clin-
ical Trials, vol. 11, no. 2, pp. 99–105, 2016.
[5] E. J. Huang and L. F. Reichardt, “Neurotrophins: roles in neu-
ronal development and function,” Annual Review of Neurosci-
ence, vol. 24, no. 1, pp. 677–736, 2001.
[6] M. Barbacid, “Structural and functional properties of the TRK
family of neurotrophin receptors,” Annals of the New York
Academy of Sciences, vol. 766, no. 1, pp. 442–458, 1995.
[7] W. J. Friedman and L. A. Greene, “Neurotrophin signaling via
Trks and p 75,” Experimental Cell Research, vol. 253, no. 1,
pp. 131–142, 1999.
[8] A. Nakagawara, “Trk receptor tyrosine kinases: a bridge
between cancer and neural development,” Cancer Letters,
vol. 169, no. 2, pp. 107–114, 2001.
[9] A. Ricci, S. Greco, S. Mariotta et al., “Neurotrophins and neu-
rotrophin receptors in human lung cancer,” American Journal
of Respiratory Cell and Molecular Biology, vol. 25, no. 4,
pp. 439–446, 2001.
[10] T. R. Geiger and D. S. Peeper, “Critical role for TrkB kinase
function in anoikis suppression, tumorigenesis, and metasta-
sis,” Cancer Research, vol. 67, no. 13, pp. 6221–6229, 2007.
[11] S. Douma, T. Van Laar, J. Zevenhoven, R. Meuwissen, E. Van
Garderen, and D. S. Peeper, “Suppression of anoikis and
induction of metastasis by the neurotrophic receptor TrkB,”
Nature, vol. 430, no. 7003, pp. 1034–1039, 2004.
[12] B. M. Fenner, “Truncated TrkB: beyond a dominant negative
receptor,” Cytokine & Growth Factor Reviews, vol. 23, no. 1–
2, pp. 15–24, 2012.
[13] A. Haapasalo, E. Koponen, E. Hoppe, G. Wong, and
E. Castrén, “Truncated trkB.T1 is dominant negative inhibitor
of trkB.TK+-mediated cell survival,” Biochemical and Biophys-
ical Research Communications, vol. 280, no. 5, pp. 1352–1358,
2001.
[14] T. Ishiguro, H. Ohata, A. Sato, K. Yamawaki, T. Enomoto, and
K. Okamoto, “Tumor-derived spheroids: relevance to cancer
stem cells and clinical applications,” Cancer Science, vol. 108,
no. 3, pp. 283–289, 2017.
[15] G. Roscilli, C. De Vitis, F. F. Ferrara et al., “Human lung ade-
nocarcinoma cell cultures derived frommalignant pleural effu-
sions as model system to predict patients chemosensitivity,”
Journal of Translational Medicine, vol. 14, no. 1, 2016.
[16] H. H. Popper, “Progression and metastasis of lung cancer,”
Cancer Metastasis Reviews, vol. 35, no. 1, pp. 75–91, 2016.
[17] K. J. Stelzer, “Epidemiology and prognosis of brain metasta-
ses,” Surgical Neurology International, vol. 4, Supplement 4,
pp. S192–S202, 2013.
[18] A. Ricci, C. de Vitis, A. Noto et al., “TrkB is responsible for
EMT transition in malignant pleural effusions derived cultures
from adenocarcinoma of the lung,” Cell Cycle, vol. 12, no. 11,
pp. 1696–1703, 2013.
[19] S. Odate, K. Nakamura, H. Onishi et al., “TrkB/BDNF signal-
ing pathway is a potential therapeutic target for pulmonary
large cell neuroendocrine carcinoma,” Lung Cancer, vol. 79,
no. 3, pp. 205–214, 2013.
[20] D. S. Middlemas, R. A. Lindberg, and T. Hunter, “trkB, a neu-
ral receptor protein-tyrosine kinase: evidence for a full-length
and two truncated receptors,” Molecular and Cellular Biology,
vol. 11, no. 1, pp. 143–153, 1991.
[21] Y. Zhou, S. Sinha, J. L. Schwartz, and G. R. Adami, “A subtype
of oral, laryngeal, esophageal, and lung, squamous cell carci-
noma with high levels of TrkB-T1 neurotrophin receptor
mRNA,” BMC Cancer, vol. 19, no. 1, 2019.
[22] M. Paolillo, M. Serra, and S. Schinelli, “Integrins in glioblas-
toma: still an attractive target?,” Pharmacological Research,
vol. 113, no. Part A, pp. 55–61, 2016.
[23] S. Kimura, T. Harada, K. Ijichi et al., “Expression of brain-
derived neurotrophic factor and its receptor TrkB is associated
with poor prognosis and a malignant phenotype in small cell
lung cancer,” Lung Cancer, vol. 120, pp. 98–107, 2018.
[24] P. R. Lockman, R. K. Mittapalli, K. S. Taskar et al., “Heteroge-
neous blood-tumor barrier permeability determines drug effi-
cacy in experimental brain metastases of breast cancer,”
Clinical Cancer Research, vol. 16, no. 23, pp. 5664–5678, 2010.
[25] I.-T. Lee, J.-S. Wang, W.-J. Lee et al., “The synergistic effect of
vascular cell adhesion molecule-1 and coronary artery disease
on brain-derived neurotrophic factor,” Clinica Chimica Acta,
vol. 466, pp. 194–200, 2017.
[26] C. Marcinkiewicz, Y. Taooka, Y. Yokosaki et al., “Inhibitory
effects of MLDG-containing heterodimeric disintegrins reveal
distinct structural requirements for interaction of the integrin
α9β1 with VCAM-1, tenascin-C, and osteopontin,” The Jour-
nal of Biological Chemistry, vol. 275, no. 41, pp. 31930–
31937, 2000.
[27] L. L. Smith, H. K. Cheung, L. E. Ling et al., “Osteopontin N-
terminal domain contains a cryptic adhesive sequence recog-
nized by α9β1 integrin,” The Journal of Biological Chemistry,
vol. 271, no. 45, pp. 28485–28491, 1996.
[28] I. Staniszewska, S. Zaveri, L. ValleDel et al., “Interaction of
α9β1 integrin with thrombospondin-1 promotes angiogene-
sis,” Circulation Research, vol. 100, no. 9, pp. 1308–1316, 2007.
[29] Y. Yokosaki, N. Matsuura, S. Higashiyama et al., “Identifica-
tion of the ligand binding site for the integrin α9β1 in the third
fibronectin type III repeat of tenascin-C,” The Journal of Bio-
logical Chemistry, vol. 273, no. 19, pp. 11423–11428, 1998.
[30] P. Fiorilli, D. Partridge, I. Staniszewska et al., “Integrins medi-
ate adhesion of medulloblastoma cells to tenascin and activate
pathways associated with survival and proliferation,” Labora-
tory Investigation, vol. 88, no. 11, pp. 1143–1156, 2008.
[31] C.-Y. Lin, S.-Y. Hung, H.-T. Chen et al., “Brain-derived neuro-
trophic factor increases vascular endothelial growth factor
expression and enhances angiogenesis in human chondrosar-
coma cells,” Biochemical Pharmacology, vol. 91, no. 4,
pp. 522–533, 2014.
[32] X. Kang, J. Wang, and C. Li, “Exposing the underlying rela-
tionship of cancer metastasis to metabolism and epithelial-
mesenchymal transitions,” iScience, vol. 21, pp. 754–772, 2019.
7BioMed Research International
